2021
DOI: 10.3389/fcell.2021.679544
|View full text |Cite
|
Sign up to set email alerts
|

CRISPR-Cas9 Editing of Human Histone Deubiquitinase Gene USP16 in Human Monocytic Leukemia Cell Line THP-1

Abstract: USP16 is a histone deubiquitinase which facilitates G2/M transition during the cell cycle, regulates DNA damage repair and contributes to inducible gene expression. We mutated the USP16 gene in a high differentiation clone of the acute monocytic leukemia cell line THP-1 using the CRISPR-Cas9 system and generated four homozygous knockout clones. All were able to proliferate and to differentiate in response to phorbol ester (PMA) treatment. One line was highly proliferative prior to PMA treatment and shut down p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 61 publications
0
1
0
Order By: Relevance
“…The intrinsic links between USP16 and human cancers, as well as immune response and coronary artery disease, suggest that USP16 can be a potential therapeutic target. However, inhibition or knockout of the USP16 gene may cause the upregulation of other H2A DUBs, such as USP12, BAP1, and MYSM1 [ 68 ]. Small molecule inhibitors or activators that can specifically regulate USP16 without causing the compensation of other DUBs is an exciting avenue not yet explored.…”
Section: Discussionmentioning
confidence: 99%
“…The intrinsic links between USP16 and human cancers, as well as immune response and coronary artery disease, suggest that USP16 can be a potential therapeutic target. However, inhibition or knockout of the USP16 gene may cause the upregulation of other H2A DUBs, such as USP12, BAP1, and MYSM1 [ 68 ]. Small molecule inhibitors or activators that can specifically regulate USP16 without causing the compensation of other DUBs is an exciting avenue not yet explored.…”
Section: Discussionmentioning
confidence: 99%